GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Net Income (Continuing Operations)

Eupraxia Pharmaceuticals (TSX:EPRX) Net Income (Continuing Operations) : C$-37.44 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Eupraxia Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was C$-8.33 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-37.44 Mil.

Eupraxia Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Net Income (Continuing Operations) Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial -7.30 -4.03 -23.46 -25.80 -38.86

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.41 -8.02 -6.52 -14.57 -8.33

Eupraxia Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-37.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals  (TSX:EPRX) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Eupraxia Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Net Income (Continuing Operations)
Comparable Companies
NEOE:MMED XCNQ:DTC TSXV:NGEN TSX:ONC TSX:BCT XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
EPRXF:USA
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Website
https://www.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.
Executives
James Allen Helliwell Director